New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
17:19 EDTJNJJ&J: New data shows Invokana reduces blood glucose levels
Janssen Research & Development announced new results from a 104-week Phase 3 clinical study evaluating the long-term effects of INVOKANA, canagliflozin, in patients aged 55 to 80 years with type 2 diabetes inadequately controlled on current antihyperglycemic therapies. The randomized double-blind study showed INVOKANA 100 milligrams, mg ,and 300 mg, compared to placebo, provided greater reductions in blood glucose, A1C, and greater reductions in secondary endpoints of fasting plasma glucose, body weight and systolic blood pressure. In the long-term study, DIA3010, after 104 weeks, levels of A1C, the primary endpoint, were significantly reduced with INVOKANA100 mg and 300 mg, respectively, relative to placebo: -0.49% and -0.60%. A1C, also called hemoglobin A1c, is the percent of red blood cell hemoglobin with glucose attached to it, and is an indicator of average blood glucose over the previous two to three months.3
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use